Food and Drug Administration
recently approved Xtandi (enzalutamide) to treat men with late-stage
(metastatic) castration-resistant prostate cancer that has spread or recurred,
even with medical or surgical therapy to minimize testosterone. U.S.
Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.